Currently, tumor burden is traditionally assessed using circulating biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19–9 (CA 19–9), and imaging studies, including contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI). This evidence concerns the gene CEACAM5 and neoplasm.